111, Inc.

Name

111, Inc.

Legal name

111, Inc.

Website

http://corporate.111.com.cn

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Online Pharmacy and Digital Healthcare Platform

NAICS

Pharmacies and Drug Retailers (456110), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

akta.pro secondary industries

B2B Marketplaces & Wholesale Platforms (BPAMAGAD), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Health, Wellness & Pharmacy Marketplaces (CRAFABAF)

Keywords

• Online pharmacy
• Digital healthcare platform
• B2B pharmaceutical distribution
• Internet hospital
• Drug commercialization

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Digital Commerce or Content

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. B2C Product Sales: Revenue from direct-to-consumer online pharmacy sales through 1药网 platform, selling pharmaceutical products and health products to end consumers
2. B2B Product Sales: Revenue from wholesale pharmacy platform (1药城) serving pharmacies, hospitals, and pharmaceutical distributors with integrated distribution solutions
3. Marketplace Services: Platform services revenue including digital marketing, patient education, data analytics, and pricing monitoring for pharmaceutical partners - grew 24.7% YoY in Q1 2026
4. Promotional Products: Revenue from promotional products net revenue - grew 70.2% YoY in Q1 2026
5. Healthcare Services (1诊): Online consultation, e-prescription services, and patient management services through internet hospital platform
6. SaaS and Technology Services: Cloud-based solutions, CRM tools, digital marketing tools, and supply chain technology services for pharmacies and pharmaceutical companies

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

111, Inc. operates an integrated digital healthcare platform in China through three core businesses: 1 Drugstore (B2C online pharmacy selling pharmaceutical and health products directly to consumers), 1 Clinic (Internet hospital providing online consultations and e-prescriptions), and 1 Drug Mall (B2B platform supplying pharmacies and hospitals). The platforms are unified under an S2B2C model, complemented by cloud-based SaaS tools (Yun Store, Yun Clinic, Yun Inventory, Yun CRM), an omnichannel drug commercialization service for pharma partners, and a proprietary smart supply chain spanning 8 fulfillment centers serving 550+ cities within 24 hours.

Product overview

111, Inc. (1药网) operates as an integrated digital pharmacy and healthcare platform in China, organized as a platform-plus-modules architecture. The core portfolio consists of three main products: 1药网 (B2C pharmacy platform), 1诊 (Internet hospital), and 1药城 (B2B pharmacy platform), unified under the S2B2C (Supply chain platform to enable Businesses to serve Consumers) model. These three platforms are complemented by an omnichannel drug commercialization platform for pharmaceutical partners, a suite of SaaS tools (云店铺/云诊所/云库存/云CRM) for pharmacy digitization, and the proprietary smart supply chain infrastructure spanning 8 fulfillment centers. The company also operates the 1起健康 Digital Pharmacy Alliance as a sub-brand membership program. The ecosystem integrates online and offline channels, B2B and B2C operations, self-operated and partner platforms, and medical + pharmaceutical + insurance services, enabling digital connections between patients, pharmaceutical companies, pharmacies, doctors, and insurance providers.

Differentiator

Problem solved

Functional benefit

Brands

• 1 Drugstore (1药网): B2C online pharmacy platform serving millions of consumers with pharmaceutical products and medical services
• 1 Clinic (1诊)
• 1 Drug Mall (1药城)

Products and services

• 1 Drugstore (1药网) B2C online pharmacy platform serving consumers directly with pharmaceutical products, OTC drugs, and a one-stop 'consultation + treatment' health solution integrating with 1 Clinic internet hospital.
• 1 Clinic (1诊) Internet hospital platform providing online consultations, e-prescription services, and chronic disease patient management across diabetes, oncology, psoriasis, liver cancer, and other therapeutic areas.
• 1 Drug Mall (1药城) B2B pharmaceutical distribution platform supplying pharmacies, hospitals, and medical institutions with integrated supply chain services including cloud inventory, intelligent procurement, category management, and same-day delivery.
• Diabetes Specialist Internet Hospital (糖尿病专科互联网医院)

Quantifiable outcome

• Deliveries within 24 hours to over 550 cities
• +7 more outcomes

Named customers13 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature6 records

Partnerships

20 partnerships are on record, tiered minor, core and flagship.

• BGI Genomics (华大基因)minorStrategic or Co-development Partner · 14 March 2022Strategic cooperation for COVID-19 antigen test kit distribution. 1药网 became the exclusive online retail platform for BGI's COVID-19 antigen test kits.
• Beilin Pharmaceutical (碑林药业)minorStrategic or Co-development Partner · 23 February 2022Strategic direct supply partnership for Chinese patent medicine digitalization, focusing on ENT and eye disease treatments in tier-2/3 cities.
• CONBA (康恩贝)coreStrategic or Co-development Partner · 21 December 2021First full-channel drug commercialization partner. Exclusive direct supply of prescription drugs including rivaroxaban, amoxicillin, and dirithromycin. 1药网 helps CONBA expand into grassroots markets and improve patient reach.
• Chugai Pharma China (日健中外制药)coreStrategic or Co-development Partner · 14 October 2021First full-channel commercialization partner for Chugai. Collaboration focuses on cardiovascular chronic disease management and digital healthcare services to improve patient access to innovative medicines.
• Kangyuan Pharmaceutical (康缘药业)minorStrategic or Co-development Partner · 14 October 2021Strategic cooperation for TCM digitalization, building internet specialty platforms for neurology and orthopedics, and developing doctor collaboration programs.
• Bayer Healthcare (拜耳医药保健有限公司)flagshipStrategic or Co-development Partner · 3 August 2021Deep strategic partnership making 1药网 Bayer Healthcare's only direct-supply digital platform in China. Collaboration covers full-channel drug commercialization, chronic disease management, patient education, and internet hospital services. Bayer's innovative drugs and high-quality generic medicines expand into online and offline markets through 1药网's omni-channel platform.
• Zelgen (泽璟制药)coreStrategic or Co-development Partner · 13 July 2021Strategic cooperation to build liver cancer patient management platform integrating online consultation, medication accessibility, and patient education. Platform provides integrated disease management services for liver cancer patients.
• BeiGene (百济神州)coreStrategic or Co-development Partner · 17 March 2021First-ever strategic partnership to build an online oncology disease management platform. The platform integrates 1药网's internet hospital, smart supply chain, AI solutions, and DTP drug delivery to create comprehensive cancer care services, improving patient access to innovative oncology drugs and extending doctors' service radius.
• HEC Group (东阳光集团)coreStrategic or Co-development Partner · 16 December 2020Expanded 2021 strategic cooperation covering full product lines including cardiovascular, endocrine, and anti-viral medications. Also exploring winter worm grass product commercialization.
• Nanjing Tianqing (南京正大天晴)coreStrategic or Co-development Partner · 15 December 2020Full-channel pharmaceutical commercialization partnership. 1药网 provides supply chain solutions, digital marketing, and access to 300,000+ pharmacies. First-year cooperation exceeded 100 million RMB.
• Abbott China (雅培)minorStrategic or Co-development Partner · 6 November 2020Important strategic cooperation at China International Import Expo for full-channel pharmaceutical and OTC product commercialization.
• Novartis China (诺华制药)coreStrategic or Co-development Partner · 24 September 2020Collaboration on '银聚未来' psoriasis disease management program. Jointly exploring internet+psoriasis management models leveraging 1药网's digital platform and Novartis's innovative dermatology drugs.
• Huluwa Pharmaceutical (葫芦娃药业)minorStrategic or Co-development Partner · 24 September 2020Strategic partnership for children's medicine internet commercialization, leveraging 1药网's platform to reach more families.
• Xiangxue Pharmaceutical (香雪制药)minorStrategic or Co-development Partner · 24 September 2020Full-channel commercialization partnership for traditional Chinese medicine products, leveraging digital tools for market expansion.
• Beijing Tong Ren Tang Technology (北京同仁堂科技)coreStrategic or Co-development Partner · 25 August 2020Deep strategic partnership for digital transformation of traditional Chinese medicine. 1药网 provides full-channel commercialization including online sales, B2B distribution, and dual-brand exclusive collaboration on products like 六味地黄丸, 阿胶.
• Eli Lilly China (礼来中国)flagshipStrategic or Co-development Partner · 8 May 2020Launched China's first diabetes specialty internet hospital platform within 50 days. Collaboration includes chronic disease management, patient education, and online pharmacy services. The platform provides integrated 'medical + pharmaceutical' services including consultation, prescription, and medication delivery.
• Shineway (神威药业)minorStrategic or Co-development Partner · 1 July 2018Digital distribution partnership for grassroots market expansion. Products like 神威健阳片 achieved 200%+ sales growth through the platform.
• Taikang Online (泰康在线)minorStrategic or Co-development PartnerStrategic cooperation on online medical services, medical cost control, health insurance, and PBM services to build integrated healthcare ecosystem.
• MSH China (万欣和)minorStrategic or Co-development PartnerPartnership for chronic disease management, online consultation, prescription delivery, and PBM exploration to build complete healthcare service ecosystem.
• Manulife-Sinochem (中宏保险)minorStrategic or Co-development PartnerEarly partnership on prevention, consultation, pharmacy, and PBM services to build integrated health service ecosystem.

Scale indicators14 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• JD Health International Inc. JD Health operates one of China's largest online healthcare platforms combining B2C pharmacy, B2B distribution, and consumer healthcare services. Directly comparable to 111 as a Chinese digital pharmacy/healthcare platform with integrated supply chain, though backed by JD.com's broader logistics ecosystem.
• We Doctor Group Limited: We Doctor operates one of China's largest internet hospital and appointment booking platforms, with growing online pharmacy and B2B capabilities. Directly comparable to 111's 1诊 internet hospital and overall S2B2C healthcare platform model.
• Yaoshibang (YSB): Yaoshibang is a leading Chinese B2B pharmaceutical e-commerce platform connecting upstream manufacturers with retail pharmacies. Directly comparable to 111's 1药城 B2B wholesale platform business, focused exclusively on pharmacy-to-pharmacy supply chain.
• Ping An Healthcare and Technology Company Limited: Ping An Good Doctor is a leading Chinese internet healthcare platform combining online consultation, B2C pharmacy, and consumer health management. Comparable to 111 in telehealth-plus-pharmacy integration, with stronger insurance integration through the Ping An ecosystem.
• Alibaba Health Information Technology Limited: Alibaba Health operates China's leading B2C pharmaceutical e-commerce platform on Tmall, plus B2B distribution and healthcare services. Directly competes with 111 in Chinese online pharmacy, internet hospital, and pharma commercialization services, with the structural advantage of Alibaba's traffic and logistics.
• Dingdang Health (Yiqilin): Dingdang Health operates online pharmacy and on-demand drug delivery services in China through its network of smart pharmacies. Directly comparable to 111's B2C pharmacy business, with stronger emphasis on rapid urban delivery rather than nationwide B2B distribution.

Regional players

• Amazon Pharmacy: Amazon Pharmacy operates online prescription fulfillment and B2C pharmacy services in the US. Comparable to 111's 1药网 B2C pharmacy model, though limited to US geography and lacking the integrated internet hospital and B2B distribution capabilities.

Broad incumbents

• CVS Health Corporation: CVS Health operates a vast US pharmacy retail, pharmacy benefit management, and healthcare services platform. A broad incumbent comparable to 111's integrated pharmacy-plus-services strategy, though operating in a vastly more developed market with offline retail scale.
• Walgreens Boots Alliance: Walgreens Boots Alliance is a global pharmacy retail and wholesale distribution giant. Comparable to 111 as an integrated pharmacy and healthcare services platform, though operating primarily through owned retail footprints in mature Western markets.

Emerging players

• Medlinker: Medlinker operates a Chinese internet hospital platform focused on chronic disease management and doctor collaboration. Comparable to 111's 1诊 internet hospital vertical, with stronger specialty chronic disease focus but smaller pharmacy distribution footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/111-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 111, Inc.